RobynYoungMD

Oncology • Fort Worth, TX

Breast Cancer, Hematologic Oncology

Director of Breast Cancer at The Center for Cancer and Blood Disorders

Join to view full profile

Dr. Young is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Young's full profile

Already have an account?

Office
800 W Magnolia Ave
Fort Worth, TX 76104
Phone+1 817-759-7000

Fax+1 817-759-7027

Education & Training

SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1993 - 1995
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1990 - 1993
McGovern Medical School at UTHealthClass of 1990

Certifications & Licensure

TX State Medical License 1991 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014

Clinical Trials

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Start of enrollment: 2018 Nov 28
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

85 citations
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...
C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark
Annals of Oncology. 2022-04-01
6 citations
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera
Clinical Breast Cancer. 2021-10-28
19 citations
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew M Wardley, Javier Cortes, Louise Provencher, Kathy D. Miller, A. Jo Chien
Breast Cancer Research and Treatment. 2021-02-16